← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Certara, Inc. (CERT) 10-Year Financial Performance & Capital Metrics

CERT • • Industrial / General
HealthcareHealthcare ITLife Sciences TechnologyDrug Discovery & Development
AboutCertara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.Show more
  • Revenue $385M +8.7%
  • EBITDA $66M +333.4%
  • Net Income -$12M +78.2%
  • EPS (Diluted) -0.08 +78.5%
  • Gross Margin 59.88% -0.5%
  • EBITDA Margin 17.21% +298.8%
  • Operating Margin -0.45% +96.1%
  • Net Margin -3.13% +80.0%
  • ROE -1.14% +78.0%
  • ROIC -0.11% +95.8%
  • Debt/Equity 0.29 +1.9%
  • Interest Coverage -0.08 +95.5%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓FCF machine: 20.5% free cash flow margin
  • ✓Strong 5Y sales CAGR of 13.1%
  • ✓Trading at only 1.4x book value

✗Weaknesses

  • ✗Trading more than 30% below 52-week high
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y13.06%
3Y10.42%
TTM11.47%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM134.99%

EPS CAGR

10Y-
5Y-
3Y-
TTM135.41%

ROCE

10Y Avg-0.05%
5Y Avg-0.38%
3Y Avg-0.23%
Latest-0.12%

Peer Comparison

Drug Discovery & Development
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
SLPSimulations Plus, Inc.408.17M20.26-6.2913.09%-81.66%-50.54%4.27%0.00
SDGRSchrödinger, Inc.1.13B17.47-6.80-4.21%-68.49%-54.77%0.28
CERTCertara, Inc.1.52B9.52-126.768.7%2.62%1.02%5.2%0.29

Profit & Loss

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+163.72M208.51M243.53M286.1M335.64M354.34M385.15M
Revenue Growth %-0.27%0.17%0.17%0.17%0.06%0.09%
Cost of Goods Sold+71.04M79.77M100.77M111.62M132.58M141.02M154.52M
COGS % of Revenue0.43%0.38%0.41%0.39%0.39%0.4%0.4%
Gross Profit+92.68M128.74M142.76M174.49M203.07M213.31M230.63M
Gross Margin %0.57%0.62%0.59%0.61%0.61%0.6%0.6%
Gross Profit Growth %-0.39%0.11%0.22%0.16%0.05%0.08%
Operating Expenses+97.33M109.13M167.19M160.91M170.55M254.09M232.36M
OpEx % of Revenue0.59%0.52%0.69%0.56%0.51%0.72%0.6%
Selling, General & Admin52.81M58.66M107.68M99.68M99.18M127.41M120.97M
SG&A % of Revenue0.32%0.28%0.44%0.35%0.3%0.36%0.31%
Research & Development10.48M11.63M19.64M20.38M28.2M34.17M37.1M
R&D % of Revenue0.06%0.06%0.08%0.07%0.08%0.1%0.1%
Other Operating Expenses-107K38.84M39.86M40.85M43.16M92.51M74.29M
Operating Income+-4.65M19.61M-24.42M13.58M32.52M-40.77M-1.73M
Operating Margin %-0.03%0.09%-0.1%0.05%0.1%-0.12%-0%
Operating Income Growth %-5.22%-2.25%1.56%1.39%-2.25%0.96%
EBITDA+32.36M61.17M18.33M58.69M84.99M15.3M66.3M
EBITDA Margin %0.2%0.29%0.08%0.21%0.25%0.04%0.17%
EBITDA Growth %-0.89%-0.7%2.2%0.45%-0.82%3.33%
D&A (Non-Cash Add-back)37.01M41.56M42.75M45.12M52.47M56.07M68.03M
EBIT-4.76M18.85M-24.89M13.46M36.53M-32.23M4.34M
Net Interest Income+-27.8M-28M-25.3M-16.84M-17.77M-22.92M-21.52M
Interest Income0000000
Interest Expense27.8M28M25.3M16.84M17.77M22.92M21.52M
Other Income/Expense-27.91M-28.76M-25.76M-16.95M-13.77M-14.37M-15.45M
Pretax Income+-32.56M-9.15M-50.18M-3.38M18.75M-55.14M-17.18M
Pretax Margin %-0.2%-0.04%-0.21%-0.01%0.06%-0.16%-0.04%
Income Tax+697K-225K-784K9.89M4.02M214K-5.13M
Effective Tax Rate %1.02%0.98%0.98%3.93%0.79%1%0.7%
Net Income+-33.26M-8.93M-49.4M-13.27M14.73M-55.36M-12.05M
Net Margin %-0.2%-0.04%-0.2%-0.05%0.04%-0.16%-0.03%
Net Income Growth %-0.73%-4.53%0.73%2.11%-4.76%0.78%
Net Income (Continuing)-33.26M-8.93M-49.4M-13.27M14.73M-55.36M-12.05M
Discontinued Operations0000000
Minority Interest0000000
EPS (Diluted)+-0.25-0.06-0.32-0.090.09-0.35-0.08
EPS Growth %-0.77%-4.64%0.72%2.04%-4.79%0.79%
EPS (Basic)-0.25-0.06-0.32-0.090.09-0.35-0.08
Diluted Shares Outstanding132.41M157.34M152.98M149.84M159.35M158.94M160.39M
Basic Shares Outstanding132.41M157.34M152.98M149.84M156.88M158.94M160.39M
Dividend Payout Ratio-------

Balance Sheet

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+68.93M87.52M346.58M274.73M342.25M340.2M310.85M
Cash & Short-Term Investments11.68M29.26M271.38M185.8M236.59M234.95M179.18M
Cash Only11.68M29.26M271.38M185.8M236.59M234.95M179.18M
Short-Term Investments0000000
Accounts Receivable49.88M52.36M64.8M78.31M88.81M93.26M119.08M
Days Sales Outstanding111.2191.6597.1299.996.5796.06112.85
Inventory5.53M000000
Days Inventory Outstanding28.43------
Other Current Assets3.32M2.14M3.03M1.65M8.47M5.63M4.27M
Total Non-Current Assets+982.56M949.55M922.82M1.24B1.23B1.22B1.26B
Property, Plant & Equipment5.4M4.62M3.87M15.57M16.83M12.27M16.01M
Fixed Asset Turnover30.31x45.10x62.90x18.38x19.95x28.87x24.06x
Goodwill514.27M515M518.59M703.37M717.74M716.33M757.04M
Intangible Assets459.62M428M396.44M511.82M486.78M487.04M485.21M
Long-Term Investments1.16M000000
Other Non-Current Assets1.26M1.1M1.16M2.17M5.62M3.05M2.03M
Total Assets+1.05B1.04B1.27B1.51B1.57B1.56B1.58B
Asset Turnover0.16x0.20x0.19x0.19x0.21x0.23x0.24x
Asset Growth %--0.01%0.22%0.19%0.04%-0.01%0.01%
Total Current Liabilities+65.45M63M75.34M92.22M103.16M130.02M146.09M
Accounts Payable4.91M4.92M6.39M7.46M7.53M5.17M3.5M
Days Payables Outstanding25.2222.523.1624.3920.7413.388.27
Short-Term Debt3.15M4.21M4.68M3.02M3.02M3.02M3M
Deferred Revenue (Current)1000K1000K1000K1000K1000K1000K1000K
Other Current Liabilities12.58M8.35M29.45M26.95M31.01M49.51M53.08M
Current Ratio1.05x1.39x4.60x2.98x3.32x2.62x2.13x
Quick Ratio0.97x1.39x4.60x2.98x3.32x2.62x2.13x
Cash Conversion Cycle114.42------
Total Non-Current Liabilities+493.27M482.02M371.92M377.66M390.1M386.28M370.36M
Long-Term Debt404.8M397.12M294.1M291.75M289.99M288.22M292.43M
Capital Lease Obligations48K0318K8.28M10.13M6.96M11.17M
Deferred Tax Liabilities85.67M82.16M75.89M76.1M67.35M50.83M40.42M
Other Non-Current Liabilities01.6M1.07M019.81M39.21M25.3M
Total Liabilities558.72M545.02M447.27M469.88M493.26M516.3M516.45M
Total Debt+408.28M401.38M299.37M308.38M308.13M302.57M311.9M
Net Debt396.6M372.12M27.99M122.58M71.55M67.62M132.71M
Debt / Equity0.83x0.82x0.36x0.30x0.29x0.29x0.29x
Debt / EBITDA12.62x6.56x16.33x5.25x3.63x19.78x4.70x
Net Debt / EBITDA12.26x6.08x1.53x2.09x0.84x4.42x2.00x
Interest Coverage-0.17x0.70x-0.97x0.81x1.83x-1.78x-0.08x
Total Equity+492.77M492.05M822.13M1.04B1.08B1.05B1.06B
Equity Growth %--0%0.67%0.27%0.04%-0.03%0.01%
Book Value per Share3.723.135.376.956.786.596.60
Total Shareholders' Equity492.77M492.05M822.13M1.04B1.08B1.05B1.06B
Common Stock1.32M1.32M1.53M1.6M1.6M1.6M1.62M
Retained Earnings-14.43M-12.94M-62.34M-75.6M-60.87M-116.23M-128.28M
Treasury Stock000-38K-3M-9.4M-18.18M
Accumulated OCI-1.65M-5.5M-1.59M-3.93M-8.23M-7.59M-13.42M
Minority Interest0000000

Cash Flow

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+11.59M38.02M44.81M60.39M92.54M82.75M80.47M
Operating CF Margin %0.07%0.18%0.18%0.21%0.28%0.23%0.21%
Operating CF Growth %-2.28%0.18%0.35%0.53%-0.11%-0.03%
Net Income-33.26M-8.93M-49.4M-13.27M14.73M-55.36M-12.05M
Depreciation & Amortization37.01M41.56M42.75M45.12M54.01M57.6M68.03M
Stock-Based Compensation1.71M1.69M64.51M29.48M30.35M28.3M34.77M
Deferred Taxes-3.55M-6.7M-7.83M-1.18M00-12.7M
Other Non-Cash Items1.36M1.66M1.49M3.16M8.34M51.35M10.59M
Working Capital Changes8.32M8.74M-6.71M-2.92M-14.88M863K-8.18M
Change in Receivables-2.03M-1.52M-3.93M-10.07M-15.01M152K-16.23M
Change in Inventory-2.61M000000
Change in Payables-6.36M10.03M2.38M000-4.76M
Cash from Investing+-73.91M-9.52M-8.61M-269.92M-27.84M-79.55M-112.37M
Capital Expenditures-11.48M-2.11M-7.94M-8.9M-1.43M-1.78M-1.63M
CapEx % of Revenue0.07%0.01%0.03%0.03%0%0.01%0%
Acquisitions-------
Investments-------
Other Investing-6.73M-7.41M00-11.1M-13.55M-19.42M
Cash from Financing+57.3M-8.49M208.21M123.39M-7.36M-9.45M-21.01M
Debt Issued (Net)-------
Equity Issued (Net)-------
Dividends Paid0000000
Share Repurchases-------
Other Financing-8.73M0-2.9M-6.08M-1.09M0-16.37M
Net Change in Cash-------
Free Cash Flow+107K28.51M36.87M51.49M91.11M80.98M78.84M
FCF Margin %0%0.14%0.15%0.18%0.27%0.23%0.2%
FCF Growth %-265.43%0.29%0.4%0.77%-0.11%-0.03%
FCF per Share0.000.180.240.340.570.510.49
FCF Conversion (FCF/Net Income)-0.35x-4.26x-0.91x-4.55x6.28x-1.49x-6.68x
Interest Paid25.71M26.43M27.61M14.17M17.27M19.09M22.74M
Taxes Paid3.17M4.11M12.28M8.6M0014.66M

Key Ratios

Metric2018201920202021202220232024
Return on Equity (ROE)-6.75%-1.81%-7.52%-1.42%1.39%-5.21%-1.14%
Return on Invested Capital (ROIC)-0.39%1.68%-2.14%1.01%2.11%-2.7%-0.11%
Gross Margin56.61%61.74%58.62%60.99%60.5%60.2%59.88%
Net Margin-20.31%-4.28%-20.28%-4.64%4.39%-15.62%-3.13%
Debt / Equity0.83x0.82x0.36x0.30x0.29x0.29x0.29x
Interest Coverage-0.17x0.70x-0.97x0.81x1.83x-1.78x-0.08x
FCF Conversion-0.35x-4.26x-0.91x-4.55x6.28x-1.49x-6.68x
Revenue Growth-27.36%16.79%17.48%17.32%5.57%8.7%

Revenue by Segment

2021202220232024
Reportable---385.15M
Reportable Growth----

Revenue by Geography

2021202220232024
Americas205.38M252.92M265.06M-
Americas Growth-23.15%4.80%-
EMEA56.41M57M63.57M-
EMEA Growth-1.05%11.52%-
Asia Pacific-25.72M25.71M-
Asia Pacific Growth---0.05%-
Asia Pac24.32M---
Asia Pac Growth----

Frequently Asked Questions

Growth & Financials

Certara, Inc. (CERT) reported $415.6M in revenue for fiscal year 2024. This represents a 154% increase from $163.7M in 2018.

Certara, Inc. (CERT) grew revenue by 8.7% over the past year. This is steady growth.

Yes, Certara, Inc. (CERT) is profitable, generating $10.9M in net income for fiscal year 2024 (-3.1% net margin).

Dividend & Returns

Certara, Inc. (CERT) has a return on equity (ROE) of -1.1%. Negative ROE indicates the company is unprofitable.

Certara, Inc. (CERT) generated $105.1M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.